Stock of the Day

November 27, 2020

Olema Pharmaceuticals (OLMA)

$10.53
-$0.03 (-0.3%)
Market Cap: $920.94M

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Trend

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) shares were modestly higher as investors weighed fresh analyst support and a new finance executive against weaker earnings expectations and the company’s recent quarterly loss.

  • Olema appointed Jason O’Byrne as chief financial officer. The leadership addition could support financial planning, capital management and the company’s continued development efforts. Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
  • Piper Sandler reaffirmed its Buy rating, while Goldman Sachs also initiated or reiterated a Buy view on OLMA. Continued bullish coverage may provide support for the stock and signals that analysts see substantial long-term value in Olema’s pipeline. Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals Olema Pharmaceuticals Receives a Buy from Goldman Sachs
  • JPMorgan lowered its price target to $46 from $52 but retained an Overweight rating. The target reduction is a negative revision, although it still implies considerable upside from recent trading levels. JPMorgan Revises Olema Pharmaceuticals Price Target
  • HC Wainwright reduced its EPS forecasts across 2026–2030, including estimates of losses of $2.44 per share in fiscal 2026 and $2.78 in 2027. The revisions point to expectations for larger or more persistent losses, despite the firm maintaining a Buy rating and $36 price target.
  • Olema’s latest quarterly results missed expectations, with a loss of $0.61 per share versus the consensus loss estimate of $0.55. Reports characterized the shares as gapping lower following the weak earnings, adding pressure to a stock already trading well below its 52-week high. Olema Pharmaceuticals Shares Gap Down Following Weak Earnings
← Previous Stock of the DayNext Stock of the Day →

Recent News